¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå
Diabetic Neuropathic Pain
»óǰÄÚµå : 1757503
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 384 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀº 2030³â±îÁö 21¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 4.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 21¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¸»ÃʽŰ溴ÁõÀº CAGR 5.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 7,020¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚÀ² ½Å°æ Àå¾Ö ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 3,350¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀº 2024³â¿¡ 4¾ï 3,350¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 8.2%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 4¾ï 2,890¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.7%¿Í 3.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀÌ ¸¸¼º ´ç´¢º´ °ü¸®¿¡¼­ ¿ì¼±¼øÀ§°¡ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀº Àå±â°£ÀÇ Ç÷´ç Á¶Àý ½ÇÆÐ·Î ÀÎÇÑ ¼è¾à¼º ½Å°æÀå¾Ö·Î Àü ¼¼°è ´ç´¢º´ ȯÀÚ(ƯÈ÷ 2Çü ´ç´¢º´ ȯÀÚ)ÀÇ »ó´ç¼ö°¡ ¾Î°í ÀÖ´Â ÁúȯÀÔ´Ï´Ù. ÀüÇüÀûÀÎ Áõ»óÀº ÁÖ·Î ÇÏÁö¿Í ´Ù¸®ÀÇ ÀÛ¿­°¨, Àú¸², µû²û°Å¸², Â´Â µíÇÑ °¨°¢À¸·Î ´ç´¢º´¼º ¸»ÃʽŰ溴Áõ(DPN)ÀÇ Æ¯Â¡ÀûÀÎ Áõ»óÀÔ´Ï´Ù. Àü ¼¼°è¿¡¼­ ´ç´¢º´ À¯º´·üÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó °ü·Ã ½Å°æº´Áõ ÇÕº´Áõ ¹ß»ý·üÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀº ÀÓ»ó ¹× Ä¡·á¿¡¼­ ´õ¿í Áß¿äÇÑ ÃÊÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ ÁúȯÀº »îÀÇ Áú, ¿îµ¿ ´É·Â, ¼ö¸éÀ» ½É°¢ÇÏ°Ô ÀúÇØÇϰí, ¿ì¿ïÁõ, ½Åü Àå¾Ö, ÀÇ·á ¼­ºñ½º ÀÌ¿ë Áõ°¡ÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹ÌÃæÁ· ¼ö¿ä´Â º¹ÀâÇϰí Áö¼ÓÀû ÀÌ¸ç ±âÁ¸ ÁøÅëÁ¦¿¡ ³»¼ºÀ» º¸ÀÌ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ¸¸¼º ÅëÁõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¹ÌÃæÁ· ¼ö¿ä°¡ ³ôÀº ÁúȯÀÔ´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â Áø´Ü, Ç¥Àû ÅëÁõ °ü¸®, Ç÷´ç Á¶Àý»Ó¸¸ ¾Æ´Ï¶ó ´ÙÇÐÁ¦Àû °ü¸® Àü·«¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

³­Ä¡¼º ½Å°æº´Áõ¼º ÅëÁõ¿¡ ´ëÇÑ ¾à¸®ÇÐÀû Ä¡·á´Â ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀº ¿©·¯ °¡Áö ¾àÁ¦±ºÀ¸·Î ³ª´µ¸ç, Ä¡·á È¿°ú´Â Áõ»óÀÇ ÁßÁõµµ, ȯÀÚÀÇ ³»¾à¼º, µ¿¹Ý Áúȯ¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. 1Â÷ ¼±Åà ¾à¹°¿ä¹ýÀ¸·Î´Â ÇÁ·¹°¡¹ß¸°, °¡¹ÙÆæÆ¾°ú °°Àº Ç×°æ·ÃÁ¦, µà·Ï¼¼Æ¾°ú °°Àº ¼¼·ÎÅä´Ñ ³ë¸£¿¡Çdz×ÇÁ¸° ÀçÈí¼ö ¾ïÁ¦Á¦(SNRI)°¡ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ÀÌµé ¾à¹°Àº ½Å°æ°èÀÇ ÅëÁõ Àü´ÞÀ» Á¶ÀýÇÏ´Â µ¥ µµ¿òÀ» ÁÖ¸ç, ºñ±³Àû ¾çÈ£ÇÑ À§Çè-ÆíÀÍ ÇÁ·ÎÆÄÀÏ·Î ÀÎÇØ ¼±È£µÇ´Â ¾à¹°ÀÔ´Ï´Ù.

2Â÷ Ä¡·á·Î´Â »ïȯ°è Ç׿ì¿ïÁ¦(¾Æ¹ÌÆ®¸³Æ¿¸° µî), ĸ»çÀ̽Šũ¸², ¸®µµÄ«ÀÎ ÆÐÄ¡¿Í °°Àº ¿Ü¿ëÁ¦¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´õ ½ÉÇÑ °æ¿ì¿¡´Â ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦°¡ °í·ÁµÇÁö¸¸, ¾ÈÀü¼º ¹®Á¦¿Í ÀÇÁ¸¼º À§ÇèÀ¸·Î ÀÎÇØ Àå±âÀûÀÎ »ç¿ëÀÌ Á¦Çѵ˴ϴÙ. ÃÖ±Ù ¿¬±¸¿¡¼­ ³ªÆ®·ý ä³Î Â÷´ÜÁ¦, À̿ ä³Î Á¶ÀýÁ¦, ½Å°æ ¿°Áõ °æ·Î ¾ïÁ¦Á¦¿Í °°Àº »õ·Î¿î ÀÛ¿ë±âÀüÀÌ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯Á¤ ÅëÁõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¸ð³ëŬ·Î³Î Ç×ü ¹× À¯ÀüÀÚ Ä¡·á Á¢±Ù¹ýµµ °³¹ß Ãʱ⠴ܰ迡 ÀÖÀ¸¸ç, º¸´Ù Ç¥ÀûÈ­µÈ Áúº´ º¯ÇüÀû °³ÀÔ¿¡ ´ëÇÑ ±â´ë°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

ºñ¾à¹°¿ä¹ý°ú ÅëÇÕÄ¡·á´Â Áõ»ó °ü¸®¿¡ ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀÇ ¸¸¼ºÀûÀÌ°í ´ÙÀÎÀÚÀûÀΠƯ¼ºÀ» °í·ÁÇÒ ¶§, ºñ¾à¹°Àû Ä¡·á¿Í º¸Á¶Àû °³ÀÔÀÌ Ä¡·á °èȹ¿¡ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹°¸®Ä¡·á, ½Å°æÁ¶Àý±â¼ú(°æÇÇÀû Àü±â½Å°æÀÚ±Ø, TENS µî), ÀÎÁöÇൿġ·á(CBT), ħ¼úÀº ÅëÁõ ³»¼º, ¼øÈ¯, Á¤½Å°Ç°­ °³¼±¿¡ µµ¿òÀÌ µÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. üÁß °ü¸®, ½Ä´Ü ÃÖÀûÈ­, ±Ý¿¬ µî »ýȰ½À°ü °³ÀÔÀº ½Å°æÀå¾ÖÀÇ ÁøÇàÀ» ¾ïÁ¦Çϰí Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

³»ºÐºñ Àü¹®ÀÇ, ½Å°æ°ú Àü¹®ÀÇ, ÅëÁõ Àü¹®ÀÇ, ÀçȰġ·á»ç·Î ±¸¼ºµÈ ´ÙÇÐÁ¦ Áø·áÆÀÀº ÀüÀÎÀû Ä¡·á¸¦ Á¦°øÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ¹ß °ü¸®, Ç÷´ç Á¶Àý, Ä¡·á ¼øÀÀµµ¿¡ ´ëÇÑ È¯ÀÚ ±³À°Àº Àå±âÀûÀÎ Áõ»ó °ü¸®¿Í Á·ºÎ ±Ë¾ç ¹× Àý´Ü°ú °°Àº ÇÕº´Áõ ¿¹¹æÀÇ ÇÙ½ÉÀÔ´Ï´Ù. ¿þ¾î·¯ºí µðÁöÅÐ ±â±â ¹× ¿ø°Ý ¸ð´ÏÅ͸µ Ç÷§ÆûÀº ÅëÁõ ¼öÁØ, Ȱµ¿¼º, Ä¡·á ¹ÝÀÀÀ» ÃßÀûÇϱâ À§ÇØ µµÀԵǾî Ä¡·á Á¦°øÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â ½Ç½Ã°£ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ´ç´¢º´ Àα¸ Áõ°¡, ¸¸¼º ÅëÁõÀÌ ¶Ñ·ÇÇÑ Ä¡·á ¿µ¿ªÀ̶ó´Â ÀÎ½Ä Áõ°¡, È¿°úÀûÀÎ Àå±â ÅëÁõ ¿ÏÈ­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ ¼ö¸íÀÌ ±æ¾îÁö°í ½Å°æ ¼Õ»óÀÌ ´©ÀûµÊ¿¡ µû¶ó Áö¼Ó°¡´ÉÇÑ Áõ»ó Á¶ÀýÀÇ Çʿ伺ÀÌ ´õ¿í Àý½ÇÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç°ú °°ÀÌ °í·ÉÈ­°¡ ÁøÇàµÇ°í ´ç´¢º´ À¯º´·üÀÌ ³ôÀº Áö¿ª¿¡¼­ ƯÈ÷ µÎµå·¯Áý´Ï´Ù.

ÅëÁõ ½Å°æ°úÇÐÀÇ ¹ßÀüÀº ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎÀÇ °³¼±°ú ½Å°æÀμº ÅëÁõ ¿¬±¸¿¡ ´ëÇÑ ±ÔÁ¦ ȯ°æÀÇ °³¼±°ú ÇÔ²² Ä¡·á Àü¸ÁÀ» ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µðÁöÅÐ °Ç°­ Åø¿Í ¸ð¹ÙÀÏ ¾ÛÀº ȯÀÚ°¡ ½º½º·Î Áõ»óÀ» ¸ð´ÏÅ͸µÇÏ°í ¸ÂÃã Ä¡·á °èȹÀ» ÁؼöÇϵµ·Ï µ½°í, ¿ø°Ý Áø·á¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÅëÁõ °ü·Ã ÁßÀç¿¡ ´ëÇÑ º¸Çè Àû¿ë Áõ°¡¿Í ÅëÇÕ ´ç´¢º´ °ü¸® ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ È®´ë´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °ø°ø ÀÇ·á ½Ã½ºÅÛÀÌ È¯ÀÚ Áß½ÉÀÇ ¸¸¼ºÁúȯ °ü¸®¿¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̸鼭 ´ç´¢º´¼º ½Å°æº´Áõ¼º ÅëÁõÀº ¼¼°è ÇコÄÉ¾î »ýŰ迡¼­ Áö¼ÓÀûÀ¸·Î Áß¿äÇϰí È®´ëµÇ°í ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù.

ºÎ¹®

½Å°æÀå¾Ö(¸»ÃʽŰ溴Áõ, ÀÚÀ² ½Å°æ Àå¾Ö, ±ÙÀ§ ½Å°æÀå¾Ö, ±¹¼Ò ½Å°æÀå¾Ö), ¾àÁ¦ Ŭ·¡½ºº°(Ç׿ì¿ïÁ¦, Ç×°æ·Ã¾à, ÁøÅëÁ¦), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 48°Ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diabetic Neuropathic Pain Market to Reach US$2.1 Billion by 2030

The global market for Diabetic Neuropathic Pain estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Peripheral Neuropathy, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$970.2 Million by the end of the analysis period. Growth in the Autonomic Neuropathy segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$433.5 Million While China is Forecast to Grow at 8.2% CAGR

The Diabetic Neuropathic Pain market in the U.S. is estimated at US$433.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$428.9 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Diabetic Neuropathic Pain Therapeutics Market - Key Trends & Drivers Summarized

Why Is Diabetic Neuropathic Pain Gaining Priority in Chronic Diabetes Management?

Diabetic neuropathic pain, a debilitating form of nerve damage resulting from long-term uncontrolled blood sugar levels, affects a substantial portion of the global diabetic population-especially those with type 2 diabetes. It typically presents as burning, tingling, or stabbing sensations, predominantly in the lower limbs and feet, and is a hallmark symptom of diabetic peripheral neuropathy (DPN). As diabetes prevalence continues to rise globally, the incidence of associated neuropathic complications has surged, bringing diabetic neuropathic pain into sharper clinical and therapeutic focus.

This condition significantly impairs quality of life, mobility, and sleep, contributing to depression, disability, and increased healthcare utilization. Because diabetic neuropathic pain is complex, persistent, and often resistant to conventional analgesics, it represents a high-unmet-need segment within the broader chronic pain therapeutics market. As awareness among healthcare providers and patients increases, the emphasis is shifting toward early diagnosis, targeted pain control, and multidisciplinary management strategies that go beyond glucose control alone.

How Are Pharmacological Treatments Evolving to Address Refractory Neuropathic Pain?

Therapeutic options for diabetic neuropathic pain include several drug classes, though treatment efficacy varies based on symptom severity, patient tolerance, and comorbid conditions. First-line pharmacologic therapies typically involve anticonvulsants such as pregabalin and gabapentin, and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine. These agents help modulate pain transmission in the nervous system and are preferred for their relatively favorable risk-benefit profiles.

Second-line treatments include tricyclic antidepressants (e.g., amitriptyline) and topical agents such as capsaicin cream or lidocaine patches. In more severe cases, opioid analgesics may be considered, although their long-term use is limited by safety concerns and dependency risks. Recent research is exploring newer mechanisms of action, including sodium channel blockers, ion channel modulators, and neuroinflammatory pathway inhibitors. Monoclonal antibodies and gene therapy approaches targeting specific pain pathways are also in early-stage development, offering hope for more targeted, disease-modifying interventions.

What Role Do Non-Pharmacological Therapies and Integrated Care Play in Managing Symptoms?

Given the chronic and multifactorial nature of diabetic neuropathic pain, non-pharmacologic and adjunctive interventions are increasingly being integrated into treatment plans. Physical therapy, neuromodulation techniques (e.g., transcutaneous electrical nerve stimulation or TENS), cognitive behavioral therapy (CBT), and acupuncture have shown benefit in improving pain tolerance, circulation, and mental well-being. Lifestyle interventions-such as weight management, dietary optimization, and smoking cessation-can help reduce the progression of neuropathy and improve therapeutic outcomes.

Multidisciplinary care teams, comprising endocrinologists, neurologists, pain specialists, and rehabilitation therapists, are essential for holistic care delivery. Patient education on foot care, glycemic control, and adherence to therapy is central to long-term symptom management and prevention of complications such as foot ulcers and amputations. Wearable digital devices and telemonitoring platforms are also being deployed to track pain levels, activity, and treatment response, providing real-time insights that can optimize care delivery.

What Are the Key Drivers Accelerating Growth in the Diabetic Neuropathic Pain Market?

The growth in the diabetic neuropathic pain therapeutics market is driven by several factors, including the expanding global diabetic population, increasing recognition of chronic pain as a distinct therapeutic domain, and rising demand for targeted and effective long-term pain relief solutions. As patients live longer with diabetes and experience cumulative nerve damage, the need for sustainable symptom control becomes more urgent. This trend is particularly strong in regions with aging populations and high diabetes prevalence, such as North America, Europe, and parts of Asia-Pacific.

Advancements in pain neuroscience, coupled with improved drug development pipelines and regulatory incentives for neuropathic pain research, are expanding the therapeutic landscape. Additionally, digital health tools and mobile apps are empowering patients to self-monitor symptoms and adhere to personalized care plans, while also facilitating remote consultations. Increased insurance coverage for pain-related interventions and growing investment in integrated diabetes care infrastructure are further propelling market growth. As public health systems place more emphasis on patient-centered chronic disease management, diabetic neuropathic pain will remain a critical and expanding focus area within the global healthcare ecosystem.

SCOPE OF STUDY:

The report analyzes the Diabetic Neuropathic Pain market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Neuropathy (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy); Drug Class (Antidepressants, Anticonvulsants, Analgesics); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â